EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Aleksander Chojecki, Danielle Boselli, Allison Dortilus, Issam Hamadeh, Stephanie Begley, Tommy Chen, Rupali Bose, Nikolai Podoltsev, Amer M Zeidan, Nicole Baranda Balmaceda, Abdulraheem Yacoub, Jing Ai und 7 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05735-7 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Aleksander Chojecki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, …. Hauptthemen laut MEDLINE: Pyrazoles, Nitriles, Polycythemia Vera, Pyrimidines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Wake Forest University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin and/or hematocrit levels. Patients often have symptoms such as fatigue, pruritus, and painful splenomegaly, but are also at risk of thrombosis, both venous and arterial. Ruxolitinib, a selective Janus kinase inhibitor, is approved by the US Food and Drug Administration as second-line cytoreductive treatment after intolerance or inadequate response to hydroxyurea. Although ruxolitinib has been widely used in this setting, limited data exist in the literature on ruxolitinib treatment patterns and outcomes among patients with PV in routine clinical practice. We report a retrospective, observational, cohort study of patients treated for PV with ruxolitinib across three US centers (academic and regional practice) from December 2014-December 2019. The study included 69 patients, with a median follow-up duration of 3.7 years (95% CI, 2.9–4.4). Our data demonstrate very high rates of hematocrit control (88% of patients by three months and 89% by six months); few patients required dose adjustments or suspension. No arterial thromboses were observed; however, the follow-up duration does not allow for the generation of meaningful conclusions from this. Three patients had thrombotic events; one was in the setting of a second malignancy, one post-operative, and a third related to prolonged immobility. We also found that 28% of patients initiated ruxolitinib as a result of poorly controlled platelet counts, second only to hydroxyurea intolerance (46%) as a reason to start therapy. In clinical practice, ruxolitinib continues to be effective in controlling hematocrit levels after three and six months of treatment in patients and is associated with low thrombotic risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesNitrilesPolycythemia VeraPyrimidinesThrombosisHumansFemaleMaleHematocritRetrospective StudiesAgedMiddle AgedAged, 80 and overAdultFollow-Up Studies

Stichwörter der Autor:innen

HematocritMyeloproliferative disordersPolycythemia veraRetrospective studiesRuxolitinibThrombosis

Substanzen

PyrazolesruxolitinibNitrilesPyrimidines

Autor:innen und Institutionen

  • Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC, USA. Aleksander.chojecki@atriumhealth.org.
  • Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hematology Section, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Department of Hematologic Malignancies and Cellular Therapies, Kansas University, Kansas City, KS, USA.
  • Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC, USA.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • Wake Forest University

Zitieren

APA

Chojecki, A., Boselli, D., Dortilus, A., Hamadeh, I., Begley, S., Chen, T., Bose, R., Podoltsev, N., Zeidan, A. M., Balmaceda, N. B., Yacoub, A., Ai, J., Knight, T. G., Ragon, B. K., Shah, N. A., Sanikommu, S. R., Symanowski, J., Mesa, R., & Grunwald, M. R. (2024). Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice. Annals of Hematology. https://doi.org/10.1007/s00277-024-05735-7

Vancouver

Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, et al. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice. Annals of Hematology. 2024. doi:10.1007/s00277-024-05735-7

BibTeX
@article{Chojecki2024,
  author = {Chojecki, Aleksander and Boselli, Danielle and Dortilus, Allison and Hamadeh, Issam and Begley, Stephanie and Chen, Tommy and Bose, Rupali and Podoltsev, Nikolai and Zeidan, Amer M and Balmaceda, Nicole Baranda and Yacoub, Abdulraheem and Ai, Jing and Knight, Thomas Gregory and Ragon, Brittany Knick and Shah, Nilay Arvind and Sanikommu, Srinivasa Reddy and Symanowski, James and Mesa, Ruben and Grunwald, Michael Richard},
  title = {Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05735-7}
}
Kostenlos starten →